Processing

Please wait...

Settings

Settings

1. WO1996004928 - CALCITONIN GENE RELATED PEPTIDE RECEPTOR

Publication Number WO/1996/004928
Publication Date 22.02.1996
International Application No. PCT/US1995/001587
International Filing Date 03.02.1995
Chapter 2 Demand Filed 07.03.1996
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/72 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
72for hormones
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 13/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
02of urine or of the urinary tract, e.g. urine acidifiers
A61P 15/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
C07K 14/72
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
72for hormones
Applicants
  • HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue Rockville, MD 20850-3338, US (AllExceptUS)
  • SMITHKLINE BEECHAM [US/US]; 709 Swedeland Road P.O. Box 1539 King of Prussia, PA 19406-0939, US (AllExceptUS)
  • ADAMOU, John [CA/US]; US (UsOnly)
  • AIYAR, Nambi [US/US]; US (UsOnly)
  • BERGSMA, Derk [US/US]; US (UsOnly)
  • ELSHOURBAGY, Nabil [US/US]; US (UsOnly)
  • LI, Yi [CN/US]; US (UsOnly)
  • LEE, Norman, H. [US/US]; US (UsOnly)
Inventors
  • ADAMOU, John; US
  • AIYAR, Nambi; US
  • BERGSMA, Derk; US
  • ELSHOURBAGY, Nabil; US
  • LI, Yi; US
  • LEE, Norman, H.; US
Agents
  • OLSTEIN, Elliot, M., ; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein 6 Becker Farm Road Roseland, NJ 07068, US
Priority Data
PCT/US94/0923516.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CALCITONIN GENE RELATED PEPTIDE RECEPTOR
(FR) RECEPTEUR PEPTIDIQUE APPARENTE GENETIQUEMENT A LA CALCITONINE
Abstract
(EN)
A human CGRP receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for identifying antagonists and agonists to such polypeptide. Antagonists against such polypeptides may be used therapeutically to treat cancer, arthritis, pain, diabetes, migraine and inflammation and agonists which may be used to treat hypercalcemia, obesity, hypertension, and disorders of bone remodelling. Diagnostic assays are also disclosed which detect the presence of mutations in the nucleic acid sequences which encode the receptor polypeptide.
(FR)
On décrit un récepteur polypeptidique apparenté génétiquement à la calcitonine humaine, l'ADN (l'ARN) codant pour un tel polypeptide et un procédé pour produire ce polypeptide par des techniques de recombinaison. On décrit également des procédés d'utilisation de ce polypeptide, pour identifier ses antagonistes et agonistes. Les antagonistes de ces polypeptides peuvent être utilisés en médecine pour traiter le cancer, l'arthrite, la douleur, le diabète, la migraine et l'inflammation et les agonistes peuvent être utilisés pour traiter l'hypercalcémie, l'obésité, l'hypertension et certains problèmes associés au remodelage d'os. On décrit également des systèmes diagnostiques permettant de détecter la présence de mutations dans la séquence des acides nucléiques codant pour le récepteur polypeptidique.
Latest bibliographic data on file with the International Bureau